We’re

/vairˈoo/

Veru Inc. is an oncology and urology biopharmaceutical company developing and commercializing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals .

PHARMACEUTICALS

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

LEARN MORE

VERU-111

VERU-111

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

LEARN MORE

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN)

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN)

TADFIN combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

LEARN MORE

TAMSULOSIN XR capsules and sprinkles

TAMSULOSIN XR capsules and sprinkles

A new slow release granule formulation of tamsulosin (FLOMAX®) used for the treatment of BPH, also known as enlargement of the prostate.

LEARN MORE

LATEST NEWS

2019 Q2 Investors Conference Call

May 15, 2019

Listen to the replay of the 2019 Q2 Investors Conference Call

Veru Investors Conference Call 5-15-19

News Releases Sorted By Date